Case Report
 
Immunotherapy in lung cancer: A case report and review of the literature
G.A. Watson1, S. Picardo1, J. O’Brien2, S. McGrane2, O.O. Ipadeola3, L. Coate1
1Department of Medical Oncology, University Hospital Limerick, Ireland
2Department of Radiology, University Hospital Limerick, Ireland
3Department of Pathology, University Hospital Limerick, Ireland

Article ID: 100049Z10GW2018
doi: 10.5348/100049Z10GW2018CR

Corresponding Author:
Geoffrey Alan Watson,
Mid-Western Cancer Centre,
University Hospital Limerick, Limerick, Ireland

Access full text article on other devices

  Access PDF of article on other devices

[HTML Full Text]   [PDF Full Text] [Print This Article]
[Similar article in PubMed] [Similar article in Google Scholar]



How to cite this article
Watson GA, Picardo S, O’Brien J, McGrane S, Ipadeola OO, Coate L. Immunotherapy in lung cancer: A case report and review of the literature. J Case Rep Images Oncology 2018;4:100049Z10GW2018.


ABSTRACT

Introduction: In recent years cancer immunotherapy has emerged as a ‘game changer’ in the arena of cancer therapeutics. Immune checkpoint blockade therapy in particular has been one of the most impressive advancements. By unleashing the host immune system against malignant cells, unprecedented survival rates and durable clinical responses are now being reported. These novel agents, however, are also associated with a unique spectrum of side effects. Thus, increasing use of immunotherapy merits familiarity with the clinical features of these adverse events and their subsequent management.

Case Report: A 58-year-old gentleman diagnosed with metastatic adenocarcinoma of the lung who received Nivolumab as second line treatment with a good partial response. His treatment was complicated by hypothyroidism and pneumonitis, the latter immune-mediated adverse event resulting in discontinuation of treatment. However six months after treatment cessation, the patient continues to respond radiologically and remains clinically well.

Conclusion: This case highlights the efficacy of immunotherapy, but also the difficulty in detecting and managing their unique side effects.

Keywords: Anti-PD1, Immunotherapy, Lung cancer, Nivolumab, Pneumonitis


[HTML Full Text]   [PDF Full Text]

Author Contributions
G.A. Watson – Acquisition of data, Analysis and interpretation of data, Drafting the article, Final approval of the version to be published
S. Picardo – Substantial contributions to conception and design, Revising it critically for important intellectual content, Final approval of the version to be published
J. O’Brien – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
S. McGrane – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
O.O. Ipadeola – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
L. Coate – Substantial contributions to conception and design, Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guarantor of Submission
The corresponding author is the guarantor of submission.
Source of Support
None
Consent Statement
Written informed consent was obtained from the patient for publication of this case report.
Conflict of Interest
Dr. Watson reports travel grants from BMS and Roche outside the submitted work
Dr. Coate reports a consultant/advisory role with BMS, BI, Roche, Lily, Pfizer, AstraZeneca and MSD.
Dr. Coate reports honoraria from BI, Lily, MSD, AstraZeneca and Pfizer.
Dr. Coate reports research funding from BMS, MSD, Roche and Pfizer.
Dr. Coate reports travel grants from BI, Roche, and Pfizer, outside the submitted work .
Copyright
© 2018 G.A. Watson et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.